Piotr Swat / Shutterstock.com
1 July 2025NewsEuropeMarisa Woutersen

Sanofi successfully challenges rare disease patent in Europe

French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 May 2025   Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.

More on this story

Americas
20 May 2025   Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.

More on this story

Americas
20 May 2025   Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.